Interleukin Genetics has posted revenue from continuing operations for the three months ended June 30, 2009 at $0.2m, compared to $0.5m for the same period in the prior year.
The company reported a net loss from continuing operations of $2.3m, or $0.07 per basic and diluted common share, for the second quarter of 2009, compared to $1.6m, or $0.05 for the same period in the prior year. The company recorded a net loss from discontinued operations of $1.4m or $0.05 per basic and diluted common share.
Interleukin Genetics also reported a total net loss of $3.7m, or $0.12 per basic and diluted common share, for the second quarter of 2009 compared to $1.7m or $0.05 for the same period in the prior year.
Lewis Bender, chief executive officer of Interleukin Genetics, said: The launch of our new Inherent Health brand of genetic test products marked a significant milestone for the company in the second quarter. Our product, the Weight Management genetic test, has been well received and is generating interest through a number of channels. We further executed on our key strategic objective, which is to grow our genetic testing business, by divesting the Alan James Group and signing a licensing partnership with LABEC Pharma for sales and distribution of our Heart Health product in Spain and Portugal.